Renal cell cancer: Highlights from ASCO 2020

Prof Scott Tykodi speaks to ecancer in an online interview for the virtual ASCO 2020 meeting.

Prof Tykodi discusses his main renal cancer highlights from ASCO 2020, with reference to the KEYNOTE 426 and CheckMate 214 studies. Along with, a phase II trial that investigated the use of bevacizumab and erlotinib in patients with advanced hereditary leiomyomatosis and renal cell cancer (HLRCC) or sporadic papillary renal cell cancer.

Sign up to ecancer for free to receive tailored email alerts for more videos like this.
ecancer.org/account/register.php